Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bioventus LLC
Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.
Remicade, Procrit, Aranesp and biosimilars will be subject to step therapy in limited number of Medicare Advantage plans in 2019.
The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.
Abbott Laboratories accounted for two of five original PMA approvals recorded by US FDA in August. That update and more from Medtech Insight's Approvals Tracker.
- Implantable Devices
- Large Molecule
- Other Names / Subsidiaries
- Bioventus Inc.
- Bioventus Coöperatief U.A.
- BioStructures LLC
- Bioness, Inc.